Brief: Acoramidis Continues To Demonstrate Disease-Modifying Effects In ATTR-CM
11/05/2026 15:33
May 11 (Reuters) - BridgeBio Pharma Inc BBIO.O: ACORAMIDIS CONTINUES TO DEMONSTRATE DISEASE-MODIFYING EFFECTS IN ATTR-CM, REDUCING STTR VARIABILITY AND OUTPATIENT WORSENING HEART FAILURE BRIDGEBIO PHARMA INC - ACORAMIDIS SIGNIFICANTLY REDUCES STTR VARIABILITY VERSUS PLACEBO IN ATTR-CM BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES CARDIOVASCULAR HOSPITALIZATIONS BY 34% VERSUS TAFAMIDIS Source text: ID:nGNX7nPfnm Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels